Towards evidence-based response criteria for cancer immunotherapy

Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe...

Descripción completa

Detalles Bibliográficos
Autores principales: Garralda, Elena, Laurie, Scott A., Seymour, Lesley, de Vries, Elisabeth G. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209139/
https://www.ncbi.nlm.nih.gov/pubmed/37225715
http://dx.doi.org/10.1038/s41467-023-38837-3
Descripción
Sumario:Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe which next steps are required to test its validity and how novel approaches for response criteria might be developed and included.

Ejemplares similares